Clinical Trial: Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07389187) titled 'Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)' on Dec. 28, 2025.

Brief Summary: This open-label, single-arm study evaluates the safety and preliminary efficacy of LC-K76 combined with Tislelizumab and ADT in 10 patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who progressed on prior therapies. Participants will receive oral LC-K76 and intravenous Tislelizumab for a 24-week treatment period.

Study Start Date: Feb., 2026

Study Type: INTERVENTIONAL

Condition: mCRPC

Intervention: DIETARY_SUPPLEMENT: LC-K76

Or...